CRNX - Crinetics gains as late-stage trial for lead drug succeeds
2024-03-19 07:04:13 ET
More on Crinetics Pharmaceuticals
- Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
- Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
- Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug
- Citi starts Crinetics at buy, cites upcoming data for lead drug
- Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals